Mylan Laboratories to Enter Japan's Generic Drug Market (Japan)
This article was originally published in PharmAsia News
Executive Summary
Mylan Laboratories Inc., the number three generic drug producer in the world, is working to break into Japan's generic market. Recently Mylan bought out the generic end of Germany's Merck KGaA. The Merck deal gave Mylan control of subsidiaries selling generics in 90 countries around the world. Among these companies is the Japan-based Merck Seiyaku Ltd. Mylan plans to work with Seiyaku to expand its generic business across the country, especially production of slow-release formulas, Mylan's specialty. Seiyaku will also team up with India's Matric Laboratories Ltd., which is also an affiliate of Mylan. The two companies will work together to expand Matrix's active pharmaceutical ingredient business in Japan. (Click here for more